A comparative study of serum α-βA immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer

Anticancer Research

Volumn 16, Issue 6 B, 1996, Pages 3827-3832

  Phocas, I ^a   Sarandakou, A ^a   Sikiotis, K ^a   Rizos, D ^a   Kalambokis, D ^a   Zourlas, P A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

A i.r inhihin; Benien ovarian tumors; CA125; CEA; Monitoring of ovarian cancer; Mucinous cystadenocarcinoma of the ovary

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; INHIBIN; PROTEIN SUBUNIT; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; INHIBIN-BETA SUBUNITS; INHIBINS; MIDDLE AGED; OVARIAN NEOPLASMS; PEPTIDES; POSTMENOPAUSE; TUMOR MARKERS, BIOLOGICAL;

EID: 0030485723     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Khoo SK, Whitaker S, Jones I and MacKay E: Predictive value of serial carcinoembryonic antigen levels in long-term follow-up of ovarian cancer. Cancer 43: 2471-2478, 1979.
2. Tholander B, Taube A, Lindgren A, Sjoberg O, Stendahl U, Kiviranta A, Hallman K, Holm L, Weiner E and Tamsen L: Pretreatment serum levels of CA125, carcinoembryonic antigen, tissue polypeptide antigen and placental alkaline phosphtase, in patients with ovarian carcinoma, borderline tumors or benign adnexal masses: Relevance of differential diagnosis. Gynecol Oncol 39:16-25, 1990.
3. Van Nagell JR, Donaldson ES, Gay EC, Sharkey RM, Rayburn P and Goldenberg DM: Carcinoemhryonic antigen in ovarian epithelial cystadenocarcinomas. The prognostic value of tumor and serial plasma determinations. Cancer-41: 2335-2340, 1978.
4. Fleuren GJ, Nap M, Aalders JG, Trimbos JB, Henk A and DeBruijn WA: Explanation of the limited correlation between tumor CA125 eontent and serum CA125 antigen levels in patients with ovarian tumors.Cancer 60: 2437-2442, 1987.
5. Bast RC, Feeney M, Lazarus H, Nadler LM and Colvin RB: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68: 1331-1337, 1981.
6. Kabawat SE, Bast RC, Welch WR, Knapp RC and Colvin RB: Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid and clear cell types. Am J Clin Path 79:48-104, 1983.
7. Bast RC, Klug TL, St.John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths T, Parker I and Zurawski VR: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med.309:883-887, 1983.
8. Patsner B and Mann WJ: The value of preoperative serum CA125 levels in patients with pelvic mass. Amer J Obstet Gynecol 159:873-876, 1988.
9. Shilthuis MS, Aalders JG, Bouma J, Kooi H, Fleuren GJ. Willemse PHB, De Bruijn HWA: Scrum CA125 levels in epithelial ovarian cancer: Relation with findings at second-look operations and their role in the detection of tumor recurrence. Br J Obstel Gynaecol 94:202-207, 1987.
10. Mealy DL, Burger HG, Mamers P, Jobling T, Bangah M, Quinn M, Grant P, Day AJ, Rome R and Campbell JJ: Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med. 329: 1539-1542, 1993.
11. McLachlan RI, Robertson DM, Healy DL, Burger HG and de Kretser DM: Circulating immunoreactive inhibin levels during the normal human menstrual cycle. J Clin Endocrinol Metab 65:954-961, 1987.
12. Healy DL, Mamers P, Bangah M and Burger HG: Clinical and pathological aspects of inhibin. Hum Reprod 8(Suppl 2):138-140, 1993.
13. Blaakaer J, Micic S, Morris ID, Hording U, Bennett P, Toftager-Larsen K, Djursing H and Bock JE: Immunoreactive inhibin-production in postmrnopausal women with malignant epithelial ovarian tumors. Eur J Obstel Gynecol and RB 52:105-110, 1993.
14. Poncelet E, Delacroix DL and Franehimont P: Development of inhibin α-βA specific two-sites immunoassays. Abstracts from 9th International Congress of Endocrinology. August 30-Sept. 5, Nice, France, 1993.
15. Poncelet E and Franchimont P: Two site enzymo-immunoassays of inhibin. In: inhibin and Inhibin-Related Proteins (Burger HG, deKrctzer D, Findlay J, Robertson D and Petraglia F, eds). Rome, Ares-Serono Symposia Publications, 1994 (3), pp 45-54.
16. Blaakaer J, Bennett P, Micic S, Toftager-Larsen K, Hording U, Bock JE and Lebech PE: The post-operative gonadotropin level in post-menopausal women with epithelial ovarian cancer. Eur J Obstet Gynecol and RB 52:111-116, 1993.
17. Canney PA, More M, Wilkinson PM and James RD: Ovarian cancer antigen CA125. A prospective clinical assessment of its role as a tumor marker. Brit J Cancer 50:765-769, 1984.
18. Zurawski VR, Knapp RC, Einforn N, Kenemans P, Mortel R, Ohmi K, Bast RC, Ritts RE and Malkasian G: An initial analysis of preoperative serum CA125 levels in patients with early stage ovarian carcinoma. Gynecol Oneol. 30:7-14, 1988.